Trials / Completed
CompletedNCT05428930
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
A Randomized, Double-blind, Active-controlled, Single-center Phase I Trial to Investigate the Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- CKD Bio Corporation · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501B in Glabellar lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKDB-501B | Intramuscular injection CKDB-501B |
| DRUG | Botox®50U | Intramuscular injection Botox®50U |
Timeline
- Start date
- 2022-06-22
- Primary completion
- 2022-10-25
- Completion
- 2022-10-25
- First posted
- 2022-06-23
- Last updated
- 2022-11-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05428930. Inclusion in this directory is not an endorsement.